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Aortic pulse wave velocity in renal transplant patients.
Background. In subjects with end-stage renal disease
(ESRD) undergoing hemodialysis, aortic pulse wave velocity
(PWV) is increased independently of blood pressure level and
mostly is a strong predictor of cardiovascular risk. Few studies
on this subject have been performed in renal transplant patients.
Methods. Aortic PWV was determined noninvasively in
106 patients with kidney transplantation and treated using a
standard immunosuppression protocol. Mean age was 43 ±
14 years. During the follow-up period (mean duration 54.3 ±
28.9 months), the following parameters were studied: character-
istics of the renal graft, degree of renal insufficiency, number of
acute rejections, cardiovascular risk factors, drug medications,
and cardiovascular complications.
Results. Aortic PWV was increased in subjects with renal
transplants independently of age and mean blood pressure.
Acute renal rejection and smoking habits were the principal
factors modulating together: the increase of aortic PWV and
the reduction of the glomerular filtration rate (GFR). The lat-
ter renal parameter was also influenced by the donor age. Two
main parameters were predictors of cardiovascular events: a
past history of cardiovascular disease and the pulse pressure ×
heart rate product, the major mechanical consequence of in-
creased PWV.
Conclusion. In renal transplant subjects, tobacco consump-
tion and mostly acute renal rejection modulate both aortic stiff-
ness and chronic renal failure independent of blood pressure
level and donor characteristics. Pulsatile stress mediates cardio-
vascular complications and predicts cardiovascular risk, partic-
ularly in the presence of increased heart rate.
Increased aortic pulse wave velocity (PWV) is an in-
dependent predictor of cardiovascular risk in subjects
with hypertension [1] and in subjects with advanced re-
nal failure [2]. Increased aortic PWV contributes, at any
given value of mean blood pressure (MBP) to increase
systolic blood pressure (SBP) and to decrease diastolic
blood pressure (DBP), leading to an increase in pulse
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pressure (PP). The SBP enhancement favors increased
oxygen myocardial consumption and cardiac hypertro-
phy, while the DBP reduction alters the coronary perfu-
sion and even creates myocardial ischemia. In addition
increased PP may distort the material of the arterial wall,
particularly when the number of pulsations per unit time
(PP multiplied by heart rate) is increased [3, 4].
In subjects with advanced renal failure undergoing
hemodialysis, increased aortic PWV has been shown
to be, independently of blood pressure and mechani-
cal stress, the stronger predictor of cardiovascular com-
plications. In milder forms of renal insufficiency, renal
function, judged by the formula of Cockcroft-Gault (ex-
pressed in mL/min/1.73 m2 and adjusted for gender), and
aortic PWV are inversely related, independently of MBP
and other conventional cardiovascular risk factors [5].
Few studies on the mechanical properties of large ar-
teries have been reported in subjects with renal insuffi-
ciency who underwent kidney transplantation. However,
it seems that alterations of arterial vessel wall structure
and function persist after renal transplantation and they
may contribute to the high cardiovascular morbidity and
mortality observed in these patients [6, 7]. This finding is
of major interest since large artery alterations, which are
related to the classical cardiovascular risk factors, might
also be related to the immunologic alterations accompa-
nying renal transplantation in these patients.
The purpose of the present study was (1) to evaluate
large artery stiffness in subjects submitted to renal trans-
plantation using the easy and reproducible measurement
of aortic PWV, (2) to evaluate whether this large artery
change was related to immunologic factors like acute re-
nal rejection, the major predictor of long-term renal dys-
function in these patients, and (3) to determine whether,
in this population, aortic PWV predicts cardiovascular
risk.
METHODS
Patients
Between August 1992 and December 2001, 202 dialy-
sis patients were transplanted at Rizk hospital (Beirut,
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Lebanon). Twelve patients died several years after trans-
plantation, four of them from cardiovascular events.
Twenty-one patients returned to dialysis and 29 were re-
ferred to their nephrologists for follow-up. The remaining
patients were contacted and 106 accepted participation in
the study. All of them were still dialysis free. The mean age
at inclusion was 43.09 ± 14.05 years. The mean duration of
transplantation at inclusion was 54.1 ± 29.2 months with
a minimum of 6 months and a maximum of 118 months.
One hundred and four patients had been on hemodial-
ysis and two had been on peritoneal dialysis prior to
transplantation, with a mean dialysis duration of 25.05 ±
28.7 months. The etiology of the renal disease was un-
known in 54 patients (51%), adult polycystic kidney dis-
ease in 13 patients (12.3%), chronic pyelonephritis in
11 patients (10.4%), chronic glomeruloneohritis in eight
patients (7.5%), IgA nephropathy in seven patients
(6.6%), diabetic nephropathy in six patients (5.7%),
systemic lupus erythematosis in three patients (2.8%),
nephroangiosclerosis in two patients (1.9%) and other
etiologies in two patients (1.9%).
Forty-six patients (43.4%) received kidneys from
living-related donors, 50 (47.2%) received kidneys from
living unrelated donors, and 10 (9.4%) received kidneys
from cadaveric donors. The donors were carefully eval-
uated prior to transplantation and only “ideal donors”
were accepted [8, 9]. Exclusion criteria related to the
donor included old age (>60 years), any history of hyper-
tension, diabetes mellitus, cardiovascular disease, renal
disease, connective tissue disease or any systemic illness,
and cancer.
The immunosuppression protocol consisted of a
quadruple sequential therapy [10, 11] with cyclosporin
started at a dose of 7 mg/kg/24 hours around the 3 to 4 days
posttransplantation after the serum creatinine has de-
creased below 2 mg/dL. Prednisone, azathioprine, and an-
tithymocyte globulins (ATG) were started at the evening,
1 day prior to transplantation from 1992 until the end of
1996. Since 1997, mycophenolate mofetil was used in-
stead of azathioprine at induction [11]. Since 2000, only
hyperimmunized patients or patients receiving a second
renal transplant (five patients) are induced with ATG,
in addition to prednisone, mycophenolate mofetil [12]
and cyclosporin, while the rest are receiving a humanized
monoclonal antibody directed against the interleukin-2
receptor, ZenapaxR [13, 14], 1 mg/kg as a single dose
on the evening of the transplantation, repeated 7 days
later and in some patients at day 14 posttransplantation.
Eighty-eight patients (83%) had immediate diuresis and
18 (17%) had delayed diuresis. There was no primary
graft failure.
Forty-two patients (39.6%) developed at least one
acute rejection episode with a total of 71 rejection
episodes and a mean of 1.69 rejection episode per pa-
tient. Acute rejection was defined as a persistent rise in
serum creatinine of at least 0.3 mg/dL with either biopsy-
proven or presumed acute rejection after having ruled
out other causes of acute renal dysfunction like obstruc-
tive, vascular, and infectious etiologies. Thirty-four re-
jection episodes (48%) were pathologically confirmed
and 37 (52%) were only presumed. Rejection episodes,
whether presumed or biopsy-proven, were treated with
steroids (3 successive days of 500 mg intravenous methyl-
prednisolone followed by progressive tapering). Biopsy-
proven episodes which failed to respond to glucocor-
ticoids (six episodes) were treated with ATG. Patients
with presumed acute rejection unresponsive to gluco-
corticoids (four episodes) underwent renal graft biopsy
for confirmation of the diagnosis before ATG was given.
The mean rise in serum creatinine during the acute re-
jection episode (highest creatinine reached − baseline
creatinine) was 1.2 mg/dL in the biopsy-proven group
and 1.3 mg/dL in the presumed group. All the rejection
episodes were successfully treated with resumption of
baseline serum creatinine in a period of 10 days in 61
cases (episodes which responded to steroids) and near
baseline (creatinine stabilized at baseline plus a mean
of 0.5 mg/dL) in 10 episodes (glucocorticoid-resistant
ones). The immunosuppressive medications taken at in-
clusion included prednisone (106 patients), cyclosporin
(88 patients), mycophenolate mofetil (55 patients), aza-
thioprine (48 patients), rapamune (13 patients), and
tacrolimus (1 patient).
Twelve patients (11.3%) had diabetes mellitus defined
as a fasting blood glucose level >7 mmol/L or on the pres-
ence of antidiabetic medication (sulfonylurea, biguanide,
and/or insulin). Fifty-one patients (48.1%) had hyperten-
sion defined as a SBP > 140 mm Hg and/or a DBP >
90 mm Hg, measured by mercury sphygmomanometer,
in the supine position, with a minimum of three casual
measurements during the last month, or when the pa-
tient was known to have hypertension and was treated
for this reason with antihypertensive medications. Fifteen
patients (14.2%) were on angiotensin-converting enzyme
(ACE) inhibitors and/or angiotensin II receptor antago-
nists (Ang IIA) for treatment of posttransplant erythro-
cytosis or for renal protection in cases of biopsy-proven
cyclosporin toxicity. The antihypertensive drugs included
ACE inhibitors (34 patients), Ang IIA (13 patients), cal-
cium channel blockers (six patients), beta blockers (18 pa-
tients), diuretics (four patients), and alpha blockers (one
patient) either alone (N = 40 patients) or in combination
(N = 23 patients). Twenty-six patients (24.5%) were re-
ceiving a statin at inclusion for hyperlipidemia and/or for
its immunomodulator effect [15].
A cardiovascular event was considered whenever a
clinical event had occurred at the coronary, cerebral, aor-
tic, or peripheral levels. Nine patients (8.5%) developed
one or more cardiovascular events at least 6 months af-
ter the renal transplantation with a total of 10 events.
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Table 1. Demographic data and standard laboratory analyses of the
renal transplant patients
Entire Subjects with Subjects with
population positive end negative end
(N = 106) point (N = 13) point (N = 93)
Age years 43.09 ± 14.05 47.2 ± 17.7 42.5 ± 13.5
Gender
Male 73 (68.9%) 9 (69.2%) 64 (68.8%)
Female 33 (31.1%) 4 (30.8%) 29 (31.2%)
Body mass index
kg/m2
26.07 ± 4.27 24.4 ± 4.7 26.3 ± 4.2
Waist/hip ratio
arbitrary units
0.96 ± 9.28 0.99 ± 10 0.96 ± 9.2
Tobacco consumption
pack-years
14.98 ± 29.3 17.1 ± 19.9 14.7 ± 30.5
Fasting blood glucose
mg/dL
98.08 ± 20.87 95.8 ± 20.5 98.2 ± 20.9
Total cholesterol
mg/dL
218.04 ± 47.3 217.8 ± 33 217.9 ± 48.4
Total cholesterol/high-
density lipoprotein
arbitrary units
4.14 ± 1.38 4.18 ± 1.2 4.13 ± 1.4
Triglycerides mg/dL 156.3 ± 94.8 147.3 ± 52.8 157.8 ± 98
Glomerular filtration
rate Cockroft-Gault
mL/min/1.73 m2
73.1 ± 19.4 49.8 ± 21.6a 75.2 ± 18.3
Values are expressed as means ± SD except for gender which is represented
by the number and the percentage of patients.
aP < 0.0001 vs. group with negative end point.
Seventeen patients (16%) had a past history of cardio-
vascular events (before transplantation) with a total of
22 events. Six patients of these developed a new event at
least 6 months after renal transplantation.
The serum creatinine concentration at discharge from
the hospital immediately after renal transplantation was
used for estimation of baseline renal function. Four pa-
tients had a serum creatinine at inclusion at least two
times greater than that at baseline.
In this study, the primary end point was the composite
of at least a doubling of the baseline serum creatinine con-
centration and/or the occurrence of a new cardiovascular
event at least 6 months after renal transplantation [16].
A total of 13 patients (12.3%) reached the primary end
point during follow-up. Tables 1 to 3 indicate the baseline
characteristics of the total renal transplant population as
well as those of the two subgroups (with a positive and a
negative end point).
Each subject provided informed consent for the study.
A questionnaire was filled for each patient and contained
information related to the recipient and to his or her fam-
ily in terms of family (first-degree relatives) history of
premature cardiovascular events (<55 years in men and
<60 years in women). The protocol was approved by the
regular local ethical committee.
Protocol
The hemodynamic measurements were performed in
the afternoon, each patient being in the supine position.
Brachial blood pressure was measured with a mercury
Table 2. Hemodynamic and transplantation-related parameters of
the renal transplant patients
Entire Subjects with Subjects with
population positive end negative end
(N = 106) point (N = 13) point (N = 93)
SBP brachial mm Hg 121.3 ± 19.8 129 ± 22.9 120.2 ± 19.2
DBP brachial mm Hg 70 ± 12.5 70.8 ± 17.4 69.9 ± 11.8
MBP brachial mm Hg 87.1 ± 13.3 90.3 ± 16.6 86.7 ± 12.8
PP brachial mm Hg 51.3 ± 16.3 58.2 ± 16.6 50.3 ± 15.4
Heart rate bpm 78.7 ± 13.3 87 ± 16.4a 77.5 ± 12.5
PP × heart rate
product mm
Hg/beat/min
4054 ± 1513 5092 ± 2056b 3909 ± 1374
Aortic PWV m/sec 11.13 ± 2.82 12.8 ± 4.3a 10.9 ± 2.5
Transplant age months 54.1 ± 29.2 42.5 ± 18.2 38 ± 13.5
Warm ischemia time
minutes
21.4 ± 4.1 22.7 ± 6.7 21.1 ± 3.6
Donor age years 38.8 ± 10.6 38.6 ± 11.1 38.8 ± 10.7
Dialysis duration
months
25.05 ± 28.7 22.3 ± 16.5 25.4 ± 30.1
Creatinine at
discharge mg/dL
1.18 ± 0.29 1.1 ± 0.25 1.2 ± 0.3
Acute rejection
nb (%)
42 (39.6%) 8 (61.5%) 34 (36.6%)
T2 ng/mL 445.7 ± 210.7 432.7 ± 191.4 447 ± 213.8
Nephrectomy (native
kidneys)
27 (25.5%) 4 (30.8%) 24 (25.8%)
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure;
MBP, mean blood pressure; PP, pulse pressure; bpm, beats per minute; PWV,
pulse wave velocity; T2, serum cyclosporin level 2 hours after the morning dose.
Values are expressed as mean ± SD except for acute rejection and nephrectomy
of native kidneys which are expressed as the numbers and the percentages of
patients.
aP < 0.05 vs. group with negative end point.
bP < 0.01 vs. group with negative end point.
Table 3. Multivariate analysis showing the variables independently
associated with an increase in aortic PWV and those independently
associated with a decrease in the glomerular filtration rate (GFR)
(estimated by the formula of Cockcroft-Gault, expressed in
mL/min/1.73 m2 and adjusted for gender) in the renal transplant
patients
Part of
Standard variance
b error of b P value explained
Aortic PWV
Age 9.37 1.72 <0.0001 26.7%
MBP 7.46 1.6 <0.0001 12.2%
Acute rejection 1.15 0.44 0.01 4%
Tobacco consumption 0.02 8.3 0.025 2.2%
GFR
Acute rejection −15.87 3.73 <0.0001 13%
Donor age −0.63 0.18 0.0005 8.5%
Tobacco consumption −0.12 6.13 0.058 3%
Abbreviations are: b , regression coefficient; MBP, mean blood pressure;
tobacco consumption expressed in pack-years.
sphygmomanometer after 15 minutes of rest. Phases I
and V of the Korotkoff sounds were considered as SBP
and DBP, respectively. The MBP was calculated from the
following formula: DBP + (SBP − DBP)/3. PP was cal-
culated as SBP-DBP. In each subject, the number of pul-
sations per unit time was calculated as PP multiplied by
heart rate (PP × heart rate product). Five measurements
2 minutes apart were averaged.
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After blood pressure determination the aortic PWV
was measured in a controlled environment at 22◦C us-
ing an automatic device, the “Complior” (Colson, Paris,
France). This method allows an online pulse wave record-
ing and automatic calculation of the PWV. The validation
of this method and its reproducibility has been previously
reported, with an intraobserver and an interobserver re-
peatability coefficients of 0.935 and 0.890, respectively
[17]. In our normotensive population, the mean value of
carotid-femoral PWV in men (aged 14 to 77 years) was
8.7 ± 1.6 m/sec, and in women (aged 23 to 66 years) was
8.21 ± 1.26 m/sec [18].
Venous blood samples were obtained after an
overnight fast. Laboratory tests included measurement of
a complete lipid profile, blood urea nitrogen (BUN), crea-
tinine, fasting blood sugar, and hemoglobin A1c (HbA1c)
(in diabetic subjects), and 24-hour urine collection for
creatinine and protein.
The formula of Cockroft-Gault was used for the esti-
mation of the glomerular filtration rate (GFR) and was
adjusted for gender (0.85 for females). The values were
expressed in mL/min/1.73 m2. Validation of the method
has been published in detail elsewhere [19, 20].
Statistical analysis
Statistical analysis was performed on NCSS 6.0.21 soft-
ware [21]. Descriptive statistics were used to evaluate the
characteristics of the renal transplant patients. Hyperten-
sion, diabetes mellitus, as well as some other parameters,
were used as dummy variables (e.g., 1, hypertensive pa-
tient; 0, normotensive patient).
Simple regression was performed to evaluate lin-
ear associations between the hemodynamic parameters
as PWV, the renal function parameters as the value
of Cockcroft-Gault in mL/min/1.73 m2 (adjusted for
gender), and the other biologic, morphologic, and ther-
apeutic variables. All the parameters showing significant
correlation with the PWV and/or the value of Cockcroft-
Gault (mL/min/1.73 m2), and those which are theoreti-
cally or historically related to theses two parameters were
integrated in a stepwise regression analysis with back-
ward elimination to determine the ones independently
associated with a significant modification of the above
parameters.
The primary end point was the composite of at least
a doubling of the baseline serum creatinine concentra-
tion and/or the occurrence of a new cardiovascular event
at least 6 months after renal transplantation. To deter-
mine the parameters associated with the occurrence of
the primary endpoint during the follow-up period, we
used the proportional hazards regression analysis with
the time variable being the follow-up time. All the param-
eters which were significantly correlated with the primary
end point in the simple regression analysis, together with
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Fig. 1. Aortic pulse wave velocity (PWV) in men and women with
kidney graft compared to normal men and women controls of the same
age (means ± SD). ∗∗∗P < 0.0001.
those which are theoretically associated with the occur-
rence of the primary end point, were integrated in the
proportional hazards regression analysis.
Student t test was used for comparison of normally dis-
tributed variables between the two subgroups (patients
who did not reach the primary end point and those who
reached the primary end-point during the follow-up pe-
riod). Dummy variables were compared between the two
subgroups using the chi-square test. A value of P ≤ 0.05
was considered significant.
RESULTS
Tables 1 and 2 indicate successively in the studied
population the demographic data and standard labora-
tory analyses (Table 1), and the hemodynamic and the
transplantation-related parameters (Table 2), including
the findings related to warm ischemia, donor age, acute
rejection, and nephrectomy of native kidneys. The only
parameters which differed significantly between the two
groups (those who reached the primary end point and
those who did not) were heart rate, PWV, and the PP ×
heart rate product (Table 2), pretransplant cardiovascular
events (46.2% vs. 11.8% in the positive end point group
vs. the negative end point group, respectively) (P < 0.01,
data not shown), altered GFR (Table 1) and finally, drug
treatment with aspirin (results not shown).
Figure 1 shows that, compared to normotensive men
and women of the same age, renal transplant patients
had significantly higher carotid-femoral PWV (P <0.0001
for both genders), despite the fact that men with kidney
graft had slightly but significantly lower MBP compared
to normal controls (87.8 ± 13.5 mm Hg vs. 94.5 ± 6.7 mm
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Table 4. Proportional hazards regression showing the parameters
associated with the occurrence of a cardiovascular event at least 6
months after renal transplantation and/or doubling of serum
creatinine
Part of
Standard variance
b error of b P value explained
Model 1
Heart rate 7.16 0.02 0.001 16.6%
Aortic PWV 0.25 9.16 0.006 12.9%
Model 2
Heart rate × PP(b) 3.7 1.6 0.02 9.3%
Pretransplant 1.16 0.6 0.04 7.5%
cardiovascular events
Abbreviations are: b , regression coefficient; PWV, pulse wave velocity; PP(b),
pulse pressure at the brachial level.
Hg, respectively) (P < 0.0001) and women with kidney
graft had a tendency toward a lower MBP compared to
their controls (85.7 ± 12.8 mm Hg vs. 89.4 ± 7 mm Hg,
respectively) (P = 0.068).
Stepwise regression analysis with backward elimina-
tion in renal transplant patients showed that in addition
to age and MBP, PWV was influenced by only two factors:
presence of acute rejection and increased tobacco con-
sumption (Table 3). The same factors influenced the de-
crease in GFR (Table 3) observed after transplantation.
The decrease in GFR was also independently influenced
by the age of the donor. Transplantation-related parame-
ters, other than acute renal rejection, were not associated
with a significant modification of the aortic PWV in the
renal transplant patients. Specifically, the graft age, the
warm ischemia time, the type of diuresis (immediate vs.
delayed), the pretransplant dialysis duration, the serum
creatinine at discharge and at the enrollment, and the
immunosuppressive drugs, mainly calcineurin inhibitors
(represented as the dose at inclusion in mg/kg/24 hours
and as the total cumulative dose), did not show any sig-
nificant association with the PWV either in univariate or
in multivariate analysis. In addition, an increase in serum
creatinine, whether secondary to acute rejection, chronic
allograft nephropathy, recurrence of the basic renal dis-
ease, or to any other etiology, was not associated with a
significant modification in the aortic PWV.
Finally, the occurrence of renal and/or cardiovascular
events following transplantation was influenced by two
factors: heart rate (P < 0.001) and PWV (P < 0.006)
(Table 4). When PP was multiplied by heart rate, this
product was a significant (P < 0.02) and independent
factor influencing cardiovascular events in transplanted
patients, in addition to a past history of cardiovascular
events (P < 0.04).
DISCUSSION
The salient finding in this study of renal transplant pa-
tients in their middle age was that aortic PWV was in-
creased, compared to normal controls of the same age,
despite a lower MBP in the renal transplant group. Fur-
thermore, independent of age and blood pressure level,
increased PWV was influenced by increased tobacco con-
sumption and acute renal rejection, two factors also im-
plicated in the mechanism of GFR reduction. The latter
was also influenced by another independent factor, the
donor age. Finally, increased PWV, mainly through its
consequences on PP and mostly the PP × heart rate
product, might influence cardiovascular events during the
follow-up.
In the present study, we used PWV as a marker of aor-
tic stiffness, since it is related to the square root of the
elasticity modulus and to the thickness/radius ratio [4].
The PWV, determined from foot-to-foot transit time in
the aorta, offers a simple, reproducible, and noninvasive
evaluation of regional aortic stiffness. Since the principal
factors modulating the level of PWV are age and blood
pressure, studies using PWV should adjust the values ob-
tained to these two parameters, as we did [18, 22, 23]. Our
results showed that in addition to recipient age and MBP,
PWV in renal transplant patients was mainly influenced
by tobacco consumption and acute renal rejection. Other
parameters like donor age, the presence in the recipient
of diabetes mellitus and/or hyperlipidemia, and the kind
of antihypertensive medications were not associated with
a significant modification of the aortic PWV.
Chronic allograft nephropathy, the major predictor of
long-term allograft dysfunction, may be secondary to
antigen-dependent and/or to antigen-independent mech-
anisms [24, 25]. In the present study, both factors were
involved, including age of donor, smoking, and acute re-
nal rejection. The major finding of this investigation was
that the two latter factors were the same factors that influ-
enced PWV. Increased tobacco consumption is a classical
cardiovascular risk factor, the role of which is well estab-
lished for cancer and atherosclerosis, mainly of the lower
limbs and of the coronary arteries. To our knowledge,
this study is the first involving tobacco consumption and
acute rejection in both the prognosis of renal function
and increased PWV in renal transplant patients.
Regarding acute renal rejection (biopsy-proven in 48%
and not documented by biopsy in 52% of the cases), it is
the first time, to our knowledge, that this immunologic
alteration has been found to be associated with increased
PWV, independent of serum creatinine. Acute rejection
might be responsible for both renal insufficiency and
changes of large artery stiffness. This association is not un-
expected since the immunologic changes induced by the
presence of the graft might be observed at the site of large
vessels, as previously reported in cardiac transplants [26].
In renal transplant patients, although increased PWV and
renal insufficiency are associated factors, it does not seem
likely that MBP or associated cardiovascular risk factors
(diabetes, hypercholesterolemia, increased tobacco con-
sumption) or even the presence of native kidneys may
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be a common denominator. Such an association has been
already observed in subjects with advanced renal failure
and even in patients with mild renal insufficiency (i.e., in
the total absence of renal graft [5]). Taken together, all
these findings indicate that, in chronic kidney diseases of
various origins, renal dysfunction may be associated not
only with arteriolar but also with large artery changes,
independently of mechanical stress and the presence of
atherosclerosis [5].
In this report, we found that old donor age was asso-
ciated with lower long-term graft survival. The decrease
of renal graft survival as function of donor age is usually
explained by reduced functional reserve in transplanted
kidneys, making them more vulnerable during procure-
ment, rejection, and even calcineurin inhibitor exposure
[27–29]. Another hypothesis could be that the cardiovas-
cular risk factors which characterize the donor influence
independently kidney reserve and thus contribute to the
developpement of chronic renal insufficiency. However,
this hypothesis has never been tested clinically.
In subjects with advanced renal failure, it has been
shown that the major predictors of cardiovascular compli-
cations were a past history of cardiovascular diseases and
mostly an increase of aortic PWV [2]. In subjects with
renal transplants, the cardiovascular complications are
less severe than in patients with end-stage renal disease
(ESRD) [30, 31]. In this study, we showed that increased
PWV was a major cardiovascular predictor, as it was
previously shown for reduced carotid arterial distensi-
bility [6]. Transplantation-related parameters, specifically
dialysis duration, the age of the graft, and the immuno-
suppressive medications were not associated with a mod-
ification of the hemodynamic parameters and were not
predictors of cardiovascular events in our study. In-
creased heart rate, a classical index of cardiovascular
risk [32], seemed to be of better predictive value. Indeed
tachycardia is frequent in renal transplants, particularly in
the presence of the native kidneys and of drug treatment
by cyclosporin or tacrolimus [33, 34]. However, in the
present study, the most interesting parameter to consider
for cardiovascular risk was the PP × heart rate product,
which represents in each individual the magnitude of pul-
satile stress on the arterial wall per unit time. On the basis
of animal and human studies [3, 35, 36], pulsatile stress,
more than steady stress, is susceptable to distort the ar-
terial wall and to promote arteriosclerosis, thus favoring
cardiovascular complications. In this context, increased
heart rate is important to consider per se in the mecha-
nism of increased pulsatility [4]. Enhanced activity of the
autonomic nervous system is a characteristic feature in
numerous subjects with renal transplants [33].
CONCLUSION
The present study has shown that increased PWV was
a distinct feature in subjects submitted to renal transplan-
tation. Independent of age and MBP, increased PWV is
influenced by increased tobacco consumption and mostly
by acute renal rejection, the principal predictive factor
of renal insufficiency during long-term follow-up. Car-
diovascular risk is directly related to increased PWV
and to increased pulsatility on the arterial wall whether
through an increase in the heart rate or in the PP × heart
rate product. Long-term studies in larger populations
are needed to evaluate whether cardiovascular risk re-
sults from immunologic or non immunologic alterations
or, more probably, from their combination. In addition,
whether immunomodulation or sympathetic nervous sys-
tem blockade could affect the cardiovascular outcome in
renal transplant patients remains to be addressed.
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